Related Experiment Video
Updated: Aug 18, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
[Hormone therapy and risk for venous thromboembolism in postmenopausal women]
1Groupe d'étude de la thrombose de Bretagne occidentale, GETBO--EA 3878, département de médecine interne et pneumologie, hôpital de la Cavale blanche, 29609 Brest Cedex.
Abstract:
Oral estrogens are associated with a two-fold to three-fold increased risk of venous thromboembolism in postmenopausal women. Absolute excess risk is low but higher than for contraceptive pills. Biological data and observational studies suggest that transdermal estrogens are associated with a lower risk for venous thromboembolism than oral estrogens but safety has yet to be proved. Whether addition of progestin plays a significant role is undetermined so far.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis I: Introduction
Venous Thrombosis IV: Nursing Management
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Menopause
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies